Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Diel

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Osteoporosis due to cancer treatment: pathogenesis and managementJ Pfeilschifter, I J Diel
Zentralblatt Fur Gynakologie|January 1, 1996
[Bisphosphonates in anti-osteolytic therapy of metastasizing breast carcinoma]I J Diel, E F Solomayer
Cancer Treatment Reviews|February 8, 2000
Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancerI J Diel, R J Cote
British Journal of Cancer|April 26, 2000
Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG)I J Diel, G R Mundy
Cancer|July 18, 2000
Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studiesI J Diel, E F Solomayer, G Bastert
Der Radiologe|September 28, 2000
[Micrometastatic cells in the bone marrow of patients with breast carcinoma]I J Diel, E F Solomayer, G Bastert
The Journal of Supportive Oncology|February 5, 2008
Adverse effects of bisphosphonates: current issuesIngo J Diel, Raoul Bergner, Knut A Grötz
Clinical Breast Cancer|March 20, 2002
Treatment of metastatic bone disease in breast cancer: bisphosphonatesI J Diel, E F Solomayer, G Bastert
Journal of Academic Ophthalmology (2017)|June 30, 2023
A Comparison of the Flipped Classroom Model for Medical Student Education in Ophthalmology before and during the COVID-19 PandemicKelly H Yom, Ryan J Diel, Pavlina S Kemp
European Journal of Cancer Care|August 3, 2006
Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial resultsJ J Body, I J Diel, D Tripathy, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Osteoporosis due to cancer treatment: pathogenesis and managementJ Pfeilschifter, I J Diel
Zentralblatt Fur Gynakologie|January 1, 1996
[Bisphosphonates in anti-osteolytic therapy of metastasizing breast carcinoma]I J Diel, E F Solomayer
Cancer Treatment Reviews|February 8, 2000
Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancerI J Diel, R J Cote
British Journal of Cancer|April 26, 2000
Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG)I J Diel, G R Mundy
Cancer|July 18, 2000
Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studiesI J Diel, E F Solomayer, G Bastert
Der Radiologe|September 28, 2000
[Micrometastatic cells in the bone marrow of patients with breast carcinoma]I J Diel, E F Solomayer, G Bastert
The Journal of Supportive Oncology|February 5, 2008
Adverse effects of bisphosphonates: current issuesIngo J Diel, Raoul Bergner, Knut A Grötz
Clinical Breast Cancer|March 20, 2002
Treatment of metastatic bone disease in breast cancer: bisphosphonatesI J Diel, E F Solomayer, G Bastert
Journal of Academic Ophthalmology (2017)|June 30, 2023
A Comparison of the Flipped Classroom Model for Medical Student Education in Ophthalmology before and during the COVID-19 PandemicKelly H Yom, Ryan J Diel, Pavlina S Kemp
European Journal of Cancer Care|August 3, 2006
Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial resultsJ J Body, I J Diel, D Tripathy, et al.
Pageof 9